(Q37196398)

18 August 2017

1 reference

title

Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials? (English)

1 reference

18 August 2017

Shou-Ching Tang

1

1 reference

18 August 2017

language of work or name

1 reference

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

481-490

1 reference

18 August 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Prognostic and predictive factors in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project random

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

A pooled analysis of bone marrow micrometastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

GnRH analogs reduce invasiveness of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

End points and United States Food and Drug Administration approval of oncology drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701781812

10.1080/07357900701781812

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference